Comment to "Recurrent Glioblastoma Treated with Recombinant Poliovirus"

Overview

Journal Chin Med J (Engl)

Specialty General Medicine

Date 2018 Nov 2

PMID 30381609

Citations 2

Authors

Peng Wang

Guang-Zhong Chen

Affiliations

Soon will be listed here.

Citing Articles

Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies.

Shah S Med Sci (Basel). 2024; 12(1).

PMID: 38249077 PMC: 10801585. DOI: 10.3390/medsci12010001.

The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways.

Bakhtiyari M, Liaghat M, Aziziyan F, Shapourian H, Yahyazadeh S, Alipour M Cell Commun Signal. 2023; 21(1):252.

PMID: 37735675 PMC: 10512514. DOI: 10.1186/s12964-023-01282-2.

References

Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708. PMC: 4201043. DOI: 10.1056/NEJMoa1308573. View

Taal W, Oosterkamp H, Walenkamp A, Dubbink H, Beerepoot L, Hanse M . Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014; 15(9):943-53. DOI: 10.1016/S1470-2045(14)70314-6. View

Nduom E, Weller M, Heimberger A . Immunosuppressive mechanisms in glioblastoma. Neuro Oncol. 2015; 17 Suppl 7:vii9-vii14. PMC: 4625890. DOI: 10.1093/neuonc/nov151. View

Desjardins A, Gromeier M, Herndon 2nd J, Beaubier N, Bolognesi D, Friedman A . Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med. 2018; 379(2):150-161. PMC: 6065102. DOI: 10.1056/NEJMoa1716435. View